Sinopharm's net profit of 606 million yuan in the first half of the year decreased by 8.97% year-on-year

Zhitong Finance App News, Sinopharm (000028.SZ) released its 2026 semi-annual performance report. In the first half year, the company achieved operating income of 36.266 billion yuan, down 1.44% year on year; operating profit of 834 million yuan, down 9.94% year on year; total profit of 827 million yuan, down 9.88% year on year; net profit attributable to shareholders of listed companies was 606 million yuan, down 8.97% year on year. The corresponding basic earnings per share fell 9.17% year on year. Revenue and profit showed a narrowing trend compared to the first quarter, weighted average net asset income The rate decreased by 0.49 percent year over year.

In half a year, the distribution sector achieved revenue of 26.539 billion yuan, a year-on-year decrease of 0.91%; net profit of 460 million yuan, a year-on-year decrease of 4.56%. Despite being affected by the continued deepening of industry policies and short-term pressure on sector operations, the company continued to narrow the decline in revenue and profit through expansion, restructuring, and refined control, showing good operational resilience. The retail sector (“Sinopharm Holdings Guoda Pharmacy Co., Ltd.”, hereinafter referred to as “Guoda Pharmacy”) achieved operating income of 10.227 billion yuan, a year-on-year decrease of 2.40%, and the decline narrowed; net profit of 0.13 billion yuan, a year-on-year decrease of 19.74%. Due to factors such as industry policy adjustments and increased market competition, the sales revenue of National University Pharmacies declined slightly; combined with changes in the sales structure, the share of sales of high-margin varieties decreased, and gross profit decreased, leading to a decline in profits.